Reaktionsgleichung
[Cl:1][C:2]1[CH:3]=[C:4]([C:8]2[N:17]([CH3:18])[C:16](=[O:19])[C:15]3[C:10](=[CH:11][CH:12]=[C:13]([OH:20])[CH:14]=3)[N:9]=2)[CH:5]=[CH:6][CH:7]=1.[N:21]12[CH2:28][CH2:27][CH:24]([CH2:25][CH2:26]1)[CH:23](O)[CH2:22]2.C1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1.N(C(OC(C)C)=O)=NC(OC(C)C)=O>O1CCCC1>[Cl:1][C:2]1[CH:3]=[C:4]([C:8]2[N:17]([CH3:18])[C:16](=[O:19])[C:15]3[C:10](=[CH:11][CH:12]=[C:13]([O:20][CH:23]4[CH:24]5[CH2:27][CH2:28][N:21]([CH2:26][CH2:25]5)[CH2:22]4)[CH:14]=3)[N:9]=2)[CH:5]=[CH:6][CH:7]=1Komponenten
6
Edukt 4
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
To a solution of 2-(3-chlorophenyl)-6-hydroxy-3-methylquinazolin-4(3H)-one (Intermediate 33A) (100 mg, 0.35 mmol), 3-quinuclidinol (44 mg, 0.35 mmol) and triphenylphosphine (137 mg, 0.35 mmol) in tetrahydrofuran (2 mL) was added dropwise diisopropyl azodicarboxylate (0.103 mL, 0.52 mmol). The reaction was stirred for 20 h. The mixture was purified by scx cartridge (1 g) followed by acidic prep hplc then scx (500 mg) to afford 2-(3-chlorophenyl)-3-methyl-6-(quinuclidin-3-yloxy)quinazolin-4(3H)-one (18 mg, 0.045 mmol).
Aufarbeitung
- customThe mixture was purified by scx cartridge (1 g)
Quellen und Nachweise
- ORD-Eintrag
- ord-8bfe56b1768448508a09fe381435f52e
- Quelldatensatz
- uspto-grants-2014_09
- Patentnummer
- US08841289B2
Verknüpfte Notizen
Wird geladen…